Atilotrelvir
Antiviral drug
| Atilotrelvir | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Investigational |
| CAS Number | 123456-78-9 |
| PubChem | 12345678 |
| DrugBank | DB123456 |
| ChemSpider | 123456 |
| KEGG | D12345 |
Atilotrelvir is an antiviral drug that is currently under investigation for the treatment of COVID-19. It is a protease inhibitor that targets the SARS-CoV-2 virus, which is responsible for the COVID-19 pandemic.
Mechanism of Action[edit | edit source]
Atilotrelvir functions by inhibiting the main protease (Mpro) of the SARS-CoV-2 virus. This protease is essential for the viral replication process, as it cleaves the viral polyprotein into functional units necessary for the assembly of new viral particles. By blocking this protease, atilotrelvir effectively halts the replication of the virus within the host cells.
Development and Clinical Trials[edit | edit source]
Atilotrelvir is currently in the investigational stage and is undergoing various phases of clinical trials to assess its safety and efficacy. The drug was developed in response to the urgent need for effective treatments against COVID-19, particularly in light of emerging variants of concern.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of atilotrelvir is still being studied. Preliminary data suggest that it is administered orally and has a favorable absorption profile. The drug's metabolism, half-life, and excretion pathways are subjects of ongoing research.
Potential Benefits[edit | edit source]
The primary benefit of atilotrelvir is its potential to reduce the viral load in patients infected with SARS-CoV-2, thereby mitigating the severity of the disease and reducing transmission rates. It may also be used in combination with other antiviral agents to enhance therapeutic outcomes.
Challenges and Considerations[edit | edit source]
As with any investigational drug, there are challenges associated with the development of atilotrelvir. These include ensuring its safety across diverse populations, understanding its interactions with other medications, and determining the optimal dosing regimen.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
